

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities nor is it calculated to invite any such offer or invitation. In particular, this announcement does not constitute and is not an offer to sell or an invitation or a solicitation of any offer to buy or subscribe for any securities in Hong Kong, the United States of America or elsewhere. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities described herein have not been and will not be registered under the U.S. Securities Act. There will be no public offering of securities in the United States of America or any jurisdiction other than Hong Kong.

Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from the United States of America or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

FOSUN 复星
復星國際有限公司
FOSUN INTERNATIONAL LIMITED
(Incorporated in Hong Kong with limited liability)
(Stock Code: 00656)

VOLUNTARY ANNOUNCEMENT

**PROPOSED LISTING OF SHANGHAI HENLIUS BIOTECH, INC.
ON THE HONG KONG STOCK EXCHANGE
AND
WITHDRAWAL OF APPLICATION FOR QUOTATION OF
SHANGHAI HENLIUS BIOTECH, INC. ON THE NATIONAL
EQUITIES EXCHANGE AND QUOTATIONS SYSTEM**

This is a voluntary announcement made by Fosun International Limited (the “**Company**”).

Proposed Listing of Shanghai Henlius on the Hong Kong Stock Exchange

The board of directors of the Company (the “**Board**”) is pleased to announce that on 27 September 2018, the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”), a subsidiary of the Company, resolved to approve the proposed listing of Shanghai Henlius Biotech, Inc. (“**Shanghai Henlius**”) on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”).

Shanghai Henlius was established in the People’s Republic of China in 2010, which is primarily engaged in research and development, manufacturing and sale of monoclonal

antibody drugs and the provision of related technical services. As at the date of this announcement, the Company, through Fosun Pharma, indirectly controls approximately 61.093% shareholding interest in Shanghai Henlius.

Withdrawal of Application for Quotation of Shanghai Henlius on the National Equities Exchange and Quotations System

Reference is made to the announcement issued by the Company on 28 December 2016 in relation to the application for quotation of Shanghai Henlius on the National Equities Exchange and Quotations System (the “**Proposed Quotation**”).

On 27 September 2018, the board of directors of Fosun Pharma resolved to approve the withdrawal by Shanghai Henlius of the application for the Proposed Quotation.

General Information

The Company will publish further announcement(s) regarding the listing of Shanghai Henlius on the Hong Kong Stock Exchange in due course or in accordance with the applicable requirements of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange.

The shareholders and potential investors of the Company are advised to note that the spin-off and listing of Shanghai Henlius is subject to, among other things, the approval of the Hong Kong Stock Exchange and China Securities Regulatory Commission, the final decision of the Board and of the boards of directors of Fosun Pharma and Shanghai Henlius, market conditions and other factors. Accordingly, the shareholders and potential investors of the Company should be aware that there is no assurance that the spin-off and listing of Shanghai Henlius will take place or as to when it may take place. Shareholders and potential investors of the Company should therefore exercise caution when dealing in the securities of the Company. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisers.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

27 September 2018

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetao, Mr. Wang Can, Ms. Kang Lan and Mr. Gong Ping; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Mr. Yang Chao and Dr. Lee Kai-Fu.